SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effectiveness of oral SCIO-469 in
patients with myelodysplastic syndromes. SCIO-469 belongs to a new class of treatments that
inhibit expression and activity of cytokines that play a role in the progression of MDS.